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There are no predictive factors for peritoneal
dialysis-associated peritonitis; however, its resolution
correlates with a cell-mediated Th1 immune response. We
tested the hypothesis that induction of receptor-interacting
protein 2 (RIP2), an assumed kinase linked with Th1
responses, is a useful marker in this clinical setting. Basal RIP2
expression was measured in human immune cells and during
dialysis-associated peritonitis. RIP2 increased with bacterial
toxin cell activation and the temporal profile for this differed
depending on immune cell involvement in the innate or
adaptive phases of the response. Importantly, RIP2
expression increased in peritoneal immune cells during
dialysis-associated peritonitis and this upregulation
correlated with clinical outcome. An early induction in
peritoneal CD14þ cells correlated with rapid resolution,
whereas minimal induction correlated with protracted
infection and with catheter loss in 36% of patients. These
latter patients had higher levels of MCP-1 consistent with a
delayed transition from innate to adaptive immunity. Our
study shows that upregulation of RIP2 is a useful marker to
monitor dialysis-associated peritonitis and in predicting the
clinical outcome of these infections.
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Resolution of an infection relies on the ability to trigger the
appropriate pathogen-specific, adaptive immune response.
Such a response can be broadly differentiated in two types
based on the profile of cytokine production.1 Cell-mediated
or Th1 immune responses are characterized by predominant
expression of interleukin-12 (IL-12) and interferon-g (IFN-
g). In contrast, antibody-mediated or Th2 responses are
characterized by predominant expression of IL-4. Many
factors such as dose of antigen, route of entry, or primary
antigen-presenting cell (APC) can determine the generation
of either type of response.2 It is becoming apparent that the
effect of most of these factors is on cells involved in innate
immunity which then influence the development of Th1 or
Th2 responses, but the molecular events that link innate with
adaptive immunity are largely uncharacterized.
In the case of peritoneal dialysis (PD)-associated perito-
nitis, clinical resolution is dependent on the development of a
cell-mediated (Th1) immune response.3–5 We currently do not
have a robust clinical or molecular indicator for the
imprinting of the response into a Th1 profile nor for the
outcome of the infection.6 Such an indicator would be highly
beneficial in discriminating PD patients with peritonitis that
can be treated ambulatory versus those requiring hospitaliza-
tion early after diagnosis. To search for such an indicator, we
investigated signaling molecules that have been associated
with the differentiation of helper T cells into effector Th1 cells.
Receptor-interacting protein 2 (RIP2), also known as
RICK or CARDIAK, is a member of the RIP family of
proteins. This group of molecules includes at least four
members (RIP1–RIP4), all of them sharing a high degree of
sequence homology particularly at the N terminus, where
they have a putative serine/threonine kinase domain.7–9 In
comparison with the other RIP family members, RIP2 stands
out as the only member that has a caspase recruitment
domain (CARD) in its C terminus. CARD-containing
proteins generally interact with one another via CARD–-
CARD homotypic interactions, and their main function is in
the activation of nuclear factor-kB (NF-kB) and/or cas-
pases.10–12 The extensive array of molecules that contain
CARD domains and the implications of such molecules in
many fundamental cell processes have focused significant
attention on RIP2.
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2007 International Society of Nephrology
Received 7 November 2006; revised 15 June 2007; accepted 10 July
2007; published online 12 September 2007
Correspondence: J Madrenas, Robarts Research Institute, Room 2.05, 100
Perth Drive, London, Ontario, Canada N6A 5K8,
E-mail: madrenas@robarts.ca
Kidney International (2007) 72, 1273–1281 1273
The function of RIP2 is unknown. Although it was
initially identified as a molecule involved in cell death
through the tumor necrosis factor (TNF) receptor family,7
overexpression studies linked RIP2 with cell proliferation and
differentiation through the NF-kB and the JNK signaling
pathways.8,9,13 This idea was strengthened by subsequent
studies using Rip2/ mice14,15 that exhibit impaired NF-kB-
dependent macrophage responses, marked decrease in
thymocyte and CD4þ T-cell proliferation upon stimulation,
and diminished IFN-g production by natural killer cells and
Th1 cells. Such a phenotype implicated RIP2 in the activation
of cells that participate in the innate and adaptive phases
of immunity, and in the generation of cell-mediated,
Th1-driven immune responses.
On the basis of these data, we examined RIP2 expression
during PD-associated peritonitis. Here, we report that RIP2
is expressed at low levels in all peripheral blood immune cells
under resting conditions, but its expression is significantly
increased upon activation with bacterial toxins acting on toll-
like receptor 4 (TLR4) or TLR2, both in vitro and in vivo
during the course of PD-associated peritonitis. The increase
in RIP2 expression occurs in neutrophil polymorphonuclear
(PMN) cells, monocytes, and T lymphocytes in a sequential
fashion during the transition of innate to adaptive immunity.
More importantly, the level of RIP2 expression in peritoneal
immune cells in the initial stages of PD-associated peritonitis
correlates with clinical outcome. Specifically, early upregula-
tion of RIP2 in peritoneal CD14þ cells correlates with rapid
resolution of infection, whereas minimal or no upregulation
of RIP2 expression correlates with protracted peritonitis,
characterized by significantly higher monocyte chemoattract
protein 1 (MCP-1) levels and resulted in catheter loss in 36%
of the patients.
RESULTS
Activation-induced upregulation of RIP2 expression
To study the regulation of RIP2 expression, we first assessed
the effect of activation on RIP2 mRNA and protein
expression in human peripheral blood mononuclear cells
(PBMC). Remarkably for a signaling molecule, we found
that, in the absence of stimulation, RIP2 expression in PBMC
was very low but increased significantly upon mitogenic
stimulation. Such an increase was observed at the mRNA
level (on average 6-fold over baseline) as detected by
Northern blot analysis (Figure 1a) and by real-time
polymerase chain reaction (PCR; Figure 1b), and at the
protein level (Figure 1c). The presence of two bands
representing transcripts of approximately 2.5 and 1.9 kb in
the Northern blot is consistent with previous data suggesting
differential splicing for RIP2 RNA.7–9 Interestingly, stimula-
tion with either phorbol-12-myristate-13-acetate or ionomy-
cin alone induced RIP2 protein expression, and the effect was
slightly increased when added together. The change in RIP2
expression was specific and not the result of an overall
increase in gene transcription as it was not observed for RIP3,
another RIP family member (Figure 1d).16
Time-dependent upregulation of RIP2 expression in blood
cell subsets upon activation
To dissect the origin of RIP2 upregulation upon PBMC
activation, we sorted the various immune cell subsets from
peripheral blood and stimulated them with cell-specific
stimuli. Upregulation of RIP2 mRNA expression was
observed in peripheral blood monocytes in response to
lipopolysaccharide (LPS), concomitantly to a TNF-a
response (Figure 2a). In these cells, RIP2 upregulation
occurred much faster than in PMN or T cells, reaching
maximum levels after 2 h of stimulation. In PMN, LPS
induced a moderate increase (four- to five-fold over baseline)
in RIP2 expression, reaching maximum expression at 8 h
(Figure 2b). In contrast, the upregulation of RIP2 in
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Figure 1 | Activation-induced upregulation of RIP2 mRNA and
protein in PBMC. (a–d) PBMCs were left unstimulated or stimulated
ex vivo with phorbol-12-myristate-13-acetate (100 ng/ml) and
ionomycin (2 mg/ml) for 18 h. RIP2 expression was determined at the
RNA level by (a) Northern Blot analysis and (b) real-time PCR, and at
the protein level by (c) Western blot analysis. RNA and protein lysates
from E6.1 cells served as a negative control, whereas HL-60, H293,
and EBV-B served as positive controls. Band intensities in (a) were
quantified and expressed as relative densitometric units. Results in
(b) are graphed as the mean7s.d. of RIP2 mRNA expression levels, as
determined by real-time PCR, for three independent experiments.
(d) Comparison of RIP2 and RIP3 mRNA expression (mean7s.d.) as
determined by real-time PCR. Results are representative of at least
two independent experiments.
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T lymphocytes in response to plate-bound anti-CD3 anti-
bodies plus IL-2 followed a different time course with a
steady increase to peak levels (11-fold over baseline)
occurring at 8 h (Figure 2c). Activation of PMN and of T
cells was confirmed by detection of IL-8 and IFN-g,
respectively. The different temporal profiles were not due to
differences in the magnitude of response to each stimulus as
maximal response was achieved for each cell type.
Upregulation of RIP2 expression can be induced through
TLRs
Next, we examined whether microbial toxins, a more
physiologically relevant stimulation, could induce such a
response (Figure 3). We observed that the Gram-negative-
associated toxin LPS, and the Gram-positive-associated
toxins peptidoglycan (PGN) and lipoteichoic acid (LTA)
induced significant upregulation of RIP2 (8- to 25-fold over
baseline levels) (Figure 3a). Because these pathogen-derived
molecules utilize TLRs to activate immune cells (TLR4 for
LPS and TLR2 for PGN and LTA),17 we next tested the
dependence of RIP2 expression on TLR signaling with the use
of TLR blocking antibodies. As expected, pretreatment of
1,25-dihydroxyvitamin D3-differentiated U937 cells with
either anti-TLR4 or anti-TLR2 blocking antibodies comple-
tely abrogated the upregulation of RIP2 mRNA in response
to Escherichia coli LPS and Staphylococcus aureus PGN,
respectively (Figure 3b and c). Our data imply that the
increase in RIP2 expression in response to bacterial challenge
is the result of signaling from TLRs.
Upregulation of RIP2 expression during a clinical infection
Once demonstrated that RIP2 expression was upregulated
upon immune cell activation by microbial toxins, and given
the temporal profile of RIP2 upregulation in different
immune cell subsets, we proceeded to test if upregulation
of RIP2 expression was occurring in the course of PD-
associated peritonitis, a clinical immune response with a
well-defined innate immune component that evolves into a
Th1 immune response.3–5.
As previously reported, during the first 2 days of PD-
associated peritonitis, we observed a very significant increase
in the number of PMN cells in the peritoneal cavity.18 After
this time, the number of PMN cells decreased, whereas the
percentage of CD14þ macrophages/dendritic cells in the
effluents increased. On the basis of these cellular dynamics,
we analyzed the expression of RIP2 mRNA by real-time PCR
in PMN and CD14þ cells (not enough T cells were
consistently obtained for RNA isolation in these clinical
samples). We found that, during PD-associated peritonitis,
RIP2 mRNA levels in PMN were increased over baseline on
the first 2 days of infection decreasing afterwards in most
cases (Figure 4a). RIP2 mRNA levels were also increased in
CD14þ cells, with 80% of patients reaching their maximum
RIP2 mRNA expression level within the first 48 h of infection
(Figure 4b). The upregulation of RIP2 in the course of PD-
associated peritonitis was corroborated at the protein level,
with an increase in RIP2 protein expression in peritoneal
mononuclear cells (mainly CD14þ cells and T lymphocytes)
from days 1 to 3 of infection (Figure 4c), a profile that covers
the innate response and its transition to a predominant
adaptive response.
Upregulation of RIP2 expression during PD-associated
peritonitis correlates with clinical outcome
Next, we compared the level of RIP2 upregulation with the
clinical outcome of PD-associated peritonitis. We observed
that patients who failed to upregulate RIP2 in peritoneal
CD14þ cells during the early stages of infection (o2-fold
above basal level) had protracted peritonitis as defined by the
need for hospitalization, catheter removal (four patients,
36%; E. coli, Citrobacter fruendii/Candida tropicalis, S. aureus,
Pseudomonas aeruginosa), and death (one patient; S. aureus
infection) (Figure 5a). In direct contrast, all patients who
upregulated RIP2 (42-fold above basal levels) within the
first 48 h of infection had conventional peritonitis (as defined
by the lack of hospital admission) with rapid resolution. The
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Figure 2 | Activation-induced upregulation of RIP2 mRNA
expression is cell-specific and time-dependent. Total RNA was
collected from (a) purified blood monocytes stimulated with LPS
(2 mg/ml); (b) purified PMN cells stimulated with LPS (2 mg/ml); and
(c) peripheral blood T cells stimulated with plate-bound anti-CD3
(5 mg/ml)þ IL-2 (20 U/ml) for the various time intervals and RIP2
expression was analyzed by real-time PCR. Levels of (a) TNF-a, (b) IL-8,
and (c) IFN-g were measured by enzyme-linked immunosorbent assay
and served as positive controls for cell activation. Results shown are
plotted as mean7s.d. and are representative of at least three
independent experiments. ***Pp0.001.
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levels of RIP2 RNA (median7s.d.) by real-time PCR in
CD14þ cells of peritoneal effluents were also significantly
higher in cases of conventional peritonitis than in protracted
ones (P¼ 0.04; Mann–Whitney U-test). This is in direct
contrast with the clinical values obtained on day 1 for the
total cell count (Figure 5b) and the percentage of neutrophils
(Figure 5c), which do not show any significant differences
between conventional and protracted peritonitis patients at
the same time point. We also failed to see a significant
difference in the levels of the proinflammatory cytokine IL-6
in the effluent at time of diagnosis (Figure 5d). It is
important to note that differences in RIP2 levels seen on the
first day of infection are not due to differences in antibiotic
treatment as the day 1 effluent was drained before the
administration of antibiotics, nor is it due to increased
numbers of CD14þ cells in the effluents, as the conventional
peritonitis group had fewer CD14þ cells than the protracted
peritonitis group (data not shown, P¼ 0.036). In addition,
no significant differences between groups were observed in
terms of medications, time on dialysis, age, previous episodes
of peritonitis, or causal pathogen (P¼ 0.1492; Table 1).
To address formally the suitability of RIP2 mRNA levels in
the prognosis of peritonitis outcome, we plotted the receiver-
operator characteristic curve for the RIP2 mRNA values, the
total cell count, and the dialysate IL-6 levels. With this test,
we found that only the receiver-operator characteristic curve
of the RIP2 mRNA levels gave an area under the curve that
was significantly different from the line of identity (P¼ 0.039;
Figure 6). The same test for total cell count or IL-6 show
lower areas under the curve that were not statistically
significant and that fell on the line of identity. On the basis
of these data, we concluded that RIP2 expression is a good
indicator of clinical outcome for PD-associated peritonitis.
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Figure 3 | Upregulation of RIP2 in response to bacterial toxins is pattern recognition receptor-dependent. (a) 1,25-Dihydroxyvitamin
D3-differentiated U937 cells were stimulated with 2 mg/ml of nontoxic (NT) LPS, E. coli LPS, P. aeruginosa LPS, S. marcescens LPS, 10 mg/ml S.
aureus PGN, and S. aureus LTA for 2 h and RIP2 mRNA expression measured by real-time PCR. (b) 1,25-Dihydroxyvitamin D3-differentiated
U937 cells were stimulated with titrating amounts of E. coli LPS in the presence/absence of anti-TLR4 antibody (10 mg/ml) or (c) titrating
amounts of S. aureus PGN in the presence/absence of anti-TLR2 antibodies (10 mg/ml). Total RNA was isolated and RIP2 expression was
analyzed by real-time PCR. Results are plotted as mean7s.d. and are representative of three independent experiments.
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Figure 4 | Upregulation of RIP2 in peritoneal immune cells during
PD-associated peritonitis. Long dwelling PD effluents from patients
with peritonitis were collected each day after diagnosis. Total RNA
was collected from (a) purified PMN (n¼ 14) and (b) CD14þ
peritoneal cells (n¼ 20) every day during the course of PD-associated
peritonitis and analyzed for the expression of RIP2 mRNA by real-time
PCR. Results are plotted as the relative RIP2 mRNA level for each
patient during the first 4 days of infection. (c) Whole-cell lysates were
prepared from peritoneal mononuclear cells (i.e., depleted of PMN)
during the first 3 days of PD-associated peritonitis and
immunoblotted for RIP2. Immunoblotting for total ERK1/2 expression
served as loading controls. Right panel: band density was quantified
from the immunoblots of six separate infections and are plotted as
mean7s.d. *Pp0.05, **Pp0.01.
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Because RIP2 expression has been linked to the ability to
mount a Th1 response, we assessed the levels of IL-12, a Th1-
inducing cytokine, in conventional vs protracted peritonitis.
For this analysis, we excluded those cases of fungal peritonitis
given their unique pathogenesis and clinical presentation. We
found a trend toward higher levels of IL-12p40 in the
peritoneal effluents from conventional PD-associated perito-
nitis when compared with the levels in peritoneal effluents of
patients with protracted PD-associated peritonitis
(P¼ 0.059) (Figure 7). Conversely, the levels of IL-8 showed
a trend toward higher levels in the protracted peritonitis
group (P¼ 0.067). More importantly, levels of MCP-1 were
significantly higher in the protracted group on day 2
(P¼ 0.036) consistent with the idea of a delayed clearance
of activated innate immune cells (Figure 7 and data not
shown). This finding is in agreement with the claim that
RIP2 expression in PD-associated peritonitis is needed for
the development of a Th1-type immune response, which has
been associated with the clearance of inflammation and a
favorable outcome for PD-associated peritonitis.5,19
Although we cannot make direct conclusions between RIP2
and IL-12p40 levels due to the initial design of the study, the
fact that both correlate with the clinical outcome implicates
RIP2 as being necessary for the development of a protective
immune response. Future studies are needed to determine if
there exists a direct correlation in IL-12 production and RIP2
levels in PD patients during episodes of peritonitis.
Expression of IL-12p35 in response to LPS and IFN-c in blood
monocytes is RIP2-dependent
To document further the link between RIP2 upregulation in
the APC and the imprinting of an immune response into the
Th1 profile,20 we directly tested whether the ability of an APC
to upregulate RIP2 expression determines its capacity to
produce IL-12p35.21 To do this, we used RNA interference for
RIP2. As expected, LPS and IFN-g stimulation of peripheral
blood monocytes upregulated RIP2 and IL-12p35 expression
(Figure 8). More importantly, RIP2 silencing with siRNA
(as shown in the bottom graph of Figure 8) significantly
inhibited the upregulation of IL-12p35 expression in
response to stimulation with LPS and IFN-g (Figure 8, top
graph). Of interest, down-modulation of RIP2 with siRNA
correlated with a slight increase of background IL-12p40 in
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Figure 5 | Early upregulation of RIP2 mRNA in peritoneal CD14þ
cells correlates with outcome of PD-associated peritonitis. (a)
RIP2 mRNA levels of patients with episodes of conventional
peritonitis (n¼ 9; K) versus patients with protracted peritonitis
(n¼ 11; J) during the first 4 days of clinical peritonitis. The day 1
clinical laboratory values for the (b) total cell counts per litre of
effluent, the (c) percentage of neutrophils, and (d) the day 1 dialysate
IL-6 levels, plotted as mean7s.d., for patients with conventional
peritonitis versus patients with protracted peritonitis. *Po0.05.
Table 1 | Demographics of the patients with PD-associated
peritonitis included in this study
Parameter
Conventional
peritonitis (n=21)
Protracted
peritonitis (n=14)
Age (years) 57.14715.48
(20–78)
57718.5 (29–92)
Sex
Male/Female 15/6 11/3
Time on PD (months) 0.75–76 0.25–81
Primary kidney disease
Glomerulonephritis 2 4
Diabetic nephropathy 10 4
Hypertension 3 1
Other 6 5
Residual renal function (Kr) 0.3370.6 0.1270.23
nPNA (g/kg/day) 0.8170.22 0.8570.25
Serum albumin (g/l) 31.5874.4 32.8573.29
Icodextran use (number of
patients)
5 5
Infectious agent
Gram-positive 13 5
Staphylococcus aureus 3 2a
Staphylococcus epidermidis 4b
Staphylococcus warneri 1
Enterococcus faecalis 4
a-haemolytic Streptococcus 2a
Corynebacterium diphtheriae 1 1
Gram-negative 6 8
Acinetobacter baumannii 2b 1
Escherichia coli 1 1
Serratia marcescens 2
Citrobacter freundii 1 1c
Pseudomonas aeruginosa 1 3
Pantoea agglomerans 1
Culture negative 3 2
Fungal 1c
Hospitalization 13
Death 1d
Catheter removal 6e
nPNA, normalized protein equivalent of nitrogen appearance; PD, peritoneal dialysis;
RIP2, receptor-interacting protein 2.
aOne a-haemolytic Streptococcus infection was concomitant with S. aureus infection.
bOne S. epidermidis infection was concomitant with Acinetobacter baumannii
infection.
cCandida tropicalis infection was concomitant with C. freundii infection.
dPatient died approximately 48 h after initial onset of peritonitis symptoms (S. aureus
infection). Patient was not hospitalized and did not have catheter removed.
eInfections resulting in catheter removal included one E. coli, one C. fruendii
concomitant with C. tropicalis, one S. aureus, and three P. aeruginosa infections
(four were studied for RIP2 expression – one E. coli, one C. fruendii/C. tropicalis, one
S. aureus, and one P. aeruginosa).
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the absence of stimulation, suggesting an involvement of
RIP2 in a regulatory feedback of the signaling pathway
leading to production of this cytokine. Further studies on this
observation are currently underway. Together, our findings
show that APCs that cannot upregulate RIP2 expression fail
to produce the Th1-inducing cytokine IL-12 upon stimula-
tion and thus will not generate a protective Th1 immune
response, providing a mechanistic explanation for the clinical
data on PD-associated peritonitis.
DISCUSSION
The results of this study show that RIP2 expression in human
immune cells increases in response to activation through
different receptors following a time-dependent, cell-type-
specific profile. Specifically, monocytes reached peak RIP2
mRNA levels earlier than PMN and T cells in line with the
notion that resident tissue macrophages initiate the response
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Figure 8 | Upregulation of IL-12p35 mRNA in blood monocytes is
RIP2-dependent. Purified peripheral blood monocytes were
transfected with or without RIP2 siRNA and left for 18 h at 371 before
stimulation with 1 mg/ml LPS and 25 ng/ml IFN-g for 6 h. Total RNA
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mean7s.d. and are representative of two independent experiments.
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to infection.22 We also show that activation-induced
upregulation of RIP2 is required for IL-12 production by
APCs. More importantly, we demonstrate that RIP2 expres-
sion is upregulated during the course of PD-associated
peritonitis, a clinical infection stimulating a protective Th1
immune response, and that this upregulation correlates with
the clinical outcome of such an infection. Thus, RIP2
upregulation may be a useful monitoring tool and prognostic
factor of PD-associated peritonitis.
The precise pathway involved in RIP2 upregulation is
currently unknown. Our results imply that such pathway(s)
emanate from different receptors, and that the type of
receptor engaged dictates the timing and peak levels of RIP2
expression. One candidate pathway is the NF-kB cascade,
shared by many receptors including T-cell receptor (TCR)
and pattern recognition receptors (PRRs) such as TLR2,
TLR4, and NOD2.23–27 The results presented here support a
role for TLR2 and TLR4, and for TCR in inducing RIP2
expression. A molecular mapping of the pathways upregulat-
ing RIP2 is currently undergoing, because it may have
biological implications on the immunomodulation of
inflammatory/adaptive responses.
What is the function of RIP2 in cell signaling? RIP2 has
been linked to activation in response to stimulation from
different receptors and pathways, but its precise role remains
unclear. RIP2 seems critical for NF-kB activation in response
to LPS-induced TLR4 signaling,14,15,28 muramyl dipeptide
(MDP)-induced NOD2 signaling,14,26,29 TCR signaling,14,15,30
and to cytokine (e.g., TNF-a and IL-1) receptor signaling.31
Such a role seems to operate on the inhibitor of NF-kB kinase
(IKK) complex, involving IRAK1 and TRAF6 for TLR-4
signaling, Bcl10 for TCR signaling, and TRAF2 and TRIP6 for
cytokine signaling. Given the arguments presented above and
our finding that TNF-a can also induce RIP2 expression, it is
plausible to conclude that RIP2 regulates its own expression
through its effects on NF-kB activation. It has also been
claimed that RIP2 has mitogen-activated protein kinase kinase
activity.32 However, the putative serine/threonine kinase
activity of RIP2 is not required for all these effects because
macrophages expressing a kinase-dead RIP2 still respond to
LPS-induced, TLR4 signaling.28 This suggests that RIP2 may
also act as an adaptor and/or have an activity other than kinase
activity. In line with this assumption, it has been reported that
RIP2 may facilitate a cross-talk between activators and
regulators of the NF-kB pathway as reported for CARD6 or
TAK1 on NOD protein signaling.31,33–35 Also, Abbott et al.29
have reported that RIP2 is required for NOD2-dependent
ubiquitinylation of NF-kB essential modulator (NEMO) and
NF-kB activation.
Although there is much evidence to support a role of RIP2 in
the induction of proinflammatory genes,11,14,15,28,36 little
evidence exists delineating the role of RIP2 in regulating antigen
presentation and T-cell polarization. Here, we report for the first
time a direct role for RIP2 in the induction of IL-12p35
expression by monocytes. This finding indicates that the
induction of Th1 immune responses is not only regulated at
the levels of the T cell as reported previously,14,15 but is also
regulated by RIP2 at the level of APC. In addition, our findings
also implicate RIP2-dependent NF-kB activation in the regula-
tion of a number of genes whose expression is also dependent on
the activation of interferon regulatory factors, such as IFN-b and
IL-12p35,37,38 further emphasizing the need for RIP2 expression
during infection to obtain optimal immune responses.
The study of the in vivo regulation of human RIP2
expression has identified this molecule as a potential
clinically relevant tool. Our data show that, during episodes
of PD-associated peritonitis, patients who have high levels of
RIP2 expression in peritoneal CD14þ cells within the first
48 h of the onset of clinical symptoms have a good prognosis
(correlating with the clinical diagnosis of conventional
PD-associated peritonitis), and clear the infection within
4 days of initial onset without complications. In sharp
contrast, 11 out of the 13 patients who failed to upregulate
RIP2 expression early on in the disease required hospitaliza-
tion and had a protracted evolution with one death and 36%
requiring catheter removal. This dichotomy is independent of
significant differences in total cells between the two groups or
the causal pathogen, although there were a significantly
greater number of CD14þ cells in the effluents of patients
with protracted peritonitis on day 1 and a significantly higher
level of MCP-1 in the effluents of patients with protracted
peritonitis on day 2. The ability for PD patients to mount
Th1-mediated adaptive immune responses correlates with
peritonitis outcome and in some cases has been associated
with a lower risk of peritonitis,5,39 likely because Th1
responses enhance the bactericidal function of macrophages,
the antigen-presenting capacity of mesothelial cells, the
clearance of neutrophils, and the development of memory
T cells.40–43 As such, our findings provide a molecular
explanation for such clinical observation, that is, that the
generation of an effective Th1 response is contingent upon
RIP2 upregulation and IL-12 production, a conclusion
consistent with the claim that Rip2/ mice have defective
Th1 immune responses14,15 and in vitro data that RIP2
enhances the anti-cytomegalovirus cell response.38
What determines the ability to upregulate RIP2 in PD
patients is unknown. The existence of allelic variations in the
regulation of RIP2, which translate in differential ability to
mount a Th1 response, is a possible explanation. There is
evidence for NOD2 polymorphisms that determine the
susceptibility or resistance to Crohn’s disease, likely through
differential regulation of the NF-kB pathway.44 Given the
regulatory role that NOD2 plays on some Th1 responses45
and its capacity to interact with RIP2,26 it is plausible to
propose that the inability of some patients to mount Th1
responses to PD-associated peritonitis is a reflection of
polymorphisms in the NOD2/RIP2/NF-kB axis.
Finally, our findings suggest that modulation of RIP2
expression may have therapeutic value to enhance beneficial
Th1 responses or downregulate those that are harmful, as
suggested by the reported therapeutic effect of RIP2 inhibition
in a mouse model of Crohn’s disease.46 In the specific case of
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PD-associated peritonitis, Th1 responses are protective while the
lack of a Th1 response correlates with prolonged inflammation
that is detrimental to the patient as it enhances peritoneal
membrane fibrosis and loss of ultrafiltration capacity.47
MATERIALS AND METHODS
Reagents
Phorbol-12-Myristate-13-Acetate, ionomycin, LPS (E. coli 0111:B4;
Serratia marcescens, P. aeruginosa), PGN (S. aureus), and LTA (S. aureus)
were obtained from Sigma-Aldrich (Oakville, Canada). Non-toxic LPS
from Rhodobacter capsulatus was provided by Dr MA Valvano
(University of Western Ontario, London, ON, Canada). Recombinant
human IL-2 was obtained from Roche Diagnostics (Laval, Canada). Cell
lineage was determined with directly labelled monoclonal antibodies
against CD3 (UCHT1) and CD19 (HIB19) (eBioscience, San Diego,
CA), CD14 (M5E2) and CD16 (3G8) (BD Biosciences, Mississauga,
Canada). For blocking experiments, 1,25-dihydroxyvitamin D3-differ-
entiated U937 cells were pretreated with anti-TLR4 (HTA125) and anti-
TLR2 (TL2.1) (eBioscience) for 30 min before stimulation.
Cells
Human cell lines U937, HL-60, Jurkat E6.1, HEK293; and the EBV-B
cell-transformed cell line (GM4672) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA)
and cultured in RPMI 1640 containing 2 mM L-glutamine, penicillin
(100 U/ml), streptomycin (100 mg/ml), 10 mM HEPES, and 10% fetal
bovine serum. U937 cell differentiation was induced with 0.1 mM of
1,25-dihydroxyvitamin D3 for 3 days.
48
Human PBMC were isolated using Ficoll-Paque Plus (Amersham
Biosciences, Baie D’urfe, Canada). PMN cells were isolated by
dextran sedimentation and hypotonic lysis of red blood cells.
Further purification was done by magnetic cell sorting (Miltenyi
Biotec, Auburn, CA, USA), and evaluated by flow cytometry. Purity
ranged from 94–99%.
PD-associated peritonitis
Patients were recruited from the London Health Sciences Centre
Peritoneal Dialysis Unit. Two-liter, long dwell (between 6 and 12 h for
day 1; and between 6 and 8 h for days 2 to 4) PD effluents were
collected from 35 patients on automated or cycler PD using either
Baxter Dianeal or Icodextran solutions, over the course of 30 months.
Diagnosis of PD-associated peritonitis was based on the presence of
abdominal pain, and a cloudy PD effluent with a leukocyte count
above 100 106/l of effluent. During episodes of PD-associated
peritonitis, patients had their long duration dwell effluents (6–12 h
for day 1–8 h for days 2–4) collected every 24 h for 4 days, whereby
the first drainage bag after the onset of symptoms and before the
initiation of antibiotic treatment was classified as day 1. Patient
demographics are representative of current PD program trends and
are outlined in Table 1. No significant differences in the distribution
of Gram-positive and -negative organisms in conventional versus
protracted peritonitis were observed. Patient participation in the
study was voluntary and research protocols were approved by the
Office of Research Ethics at the University of Western Ontario.
Peritonitis outcome was defined based on the need for hospitaliza-
tion; patients not requiring hospitalization were considered to have
conventional peritonitis, whereas patients requiring hospitalization
within the first 5 days of infection onset were considered to have
protracted peritonitis. Cells were isolated from PD effluents by
centrifugation at 1600 r.p.m. for 15 min at 41C.49
Quantitative real-time PCR
Expression of gene transcripts was quantified on the Mx4000
multiplex quantitative PCR (Stratagene, La Jolla, CA, USA) using
Brilliant SYBR Green QPCR Core Reagent kit. Total RNA was
isolated using the RNeasy Mini Kit (Qiagen, Mississauga, Canada)
or Trizol reagent (Invitrogen Life Technologies, Burlington,
Canada). Complementary DNA was synthesized using the Omnis-
cript reverse transcriptase kit (Qiagen) and oligo-dT 12–18 primer
(Invitrogen). Primers used were RIP2 F1, 50-CCATTGAGATTTCG
CATCCT-30 and RIP2 R1, 50-ATGCGCCACTTTGATAAACC-30
defining a product of 161 bp; GAPDH F1, 50-TGCACCACC
AACTGCTTAGC-30 and GAPDH R1, 50-GGCATGGACTGTGGTC
ATGAG-30 (100 bp); RIP3 F1, 50-GGCCCCAGAACTGTTTGTTA-30
and RIP3 R1, 50-CGGTTGGCAACTCAACTTCT-30 (115 bp); and
IL-12p35 F1, 50-GTTCCCATGCCTTCACCACT-30 and IL-12p35 R1,
50-TGTCTGGCCTTCTGGAGC-30 (69 bp). Each PCR product was
sequenced to confirm specificity. The relative expression levels,
based on the threshold values (Ct) of the RIP2, RIP3, or IL-12p35
gene normalized to the glyceraldehyde 3-phosphate dehydrogenase
gene, were quantified using the delta Ct method. The amplification
efficiency was calculated for each real-time PCR reaction and data
from experiments for which the efficiency of reaction was between
80 and 110% were used.
Northern blotting
Total RNA (25–30mg) from resting or activated PBMC was used for
Northern blot analysis50 using a human RIP2 cDNA probe
corresponding to nucleotides 561–1259. Membranes were hybridized
with a b-actin probe (ATCC) as a control for RNA levels.
Western blotting
Whole-cell lysates from unstimulated and stimulated PBMC and
peritoneal mononuclear cells were prepared using standard lysis
buffer. Detection of RIP2 was performed with a rabbit polyclonal
antibody against RIP2 (Cayman, Cedarlane, Hornby, Canada;
eBioscience) and signals acquired and quantified using the Fluorchem
8000 unit (Alpha Innotech, Fisher Scientific, Ottawa, Canada).
Cytokine production
Levels of TNF-a, IL-8, IFN-g, IL-12p40, and MCP-1 (BD Biosciences,
Mississauga, Canada) were determined by enzyme-linked immuno-
sorbent assay. Each supernatant was assayed in triplicate.
RNA interference
Transfection of blood monocytes was carried out by the Amaxa
Nucleofection System (ESBE Scientific, Markham, Canada). Vali-
dated duplexes of 21-oligonucleotide siRNA targeting RIP2 mRNA
were obtained from Ambion (Austin, TX) and used at a final
concentration of 100 nM.
Statistics
Unpaired Student’s t-test with Welch’s correction, Mann–Whitney
U-test, one-way ANOVA with Tukey post-test, Fisher’s exact test,
and receiver-operator characteristic curves were performed using
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA).
A difference between groups was considered significant when Po0.05.
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